ADC Therapeutics SA Earnings
The next earnings date for ADC Therapeutics SA is March 12, 2026.
They are scheduled to announce earnings after the market closes that day.
Analyst Estimates of ADC Therapeutics SA Earnings
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
ADC Therapeutics SA Earnings: Historical
More About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
“ADC Therapeutics SA Earnings” Can Refer to the ADC Therapeutics SA Earnings Date
Some people say “ADC Therapeutics SA earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my ADC Therapeutics SA position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning ADC Therapeutics SA Stock on the Earnings Date
If you own ADC Therapeutics SA stock (ADCT) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for ADC Therapeutics SA might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading ADC Therapeutics SA shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More ADC Therapeutics SA Earnings
You can contact us any time if you would like to ask questions about ADC Therapeutics SA earnings or anything else related to the stock market.